vimarsana.com
Home
Live Updates
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the ... : vimarsana.com
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the ...
An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an
Related Keywords
Boston ,
Massachusetts ,
United States ,
Florida ,
Boca Raton ,
Jason Nelson ,
Inmune Bio ,
David Moss ,
Company Current Reports On Form ,
Drug Administration ,
Drug Development ,
Inmune Bio Inc ,
Company Annual Report On Form ,
Company Quarterly Reports On Form ,
Nasdaq ,
Exchange Commission ,
Globe Newswire Inmune Bio Inc ,
Clinical Trial ,
Cumulus Neuroscience ,
Chief Executive Officer ,
Dominant Negative Tumor Necrosis Factor ,
Early Alzheimer ,
Natural Killer Cell Priming Platform ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Region ,
vimarsana.com © 2020. All Rights Reserved.